Scholarlink

<p>Von Hippel-Lindau (VHL) syndrome is an autosomal dominant hereditary disease characterized with mutiple organ tumors. Tyrosine kinase inhibitor (TKI) is one of the targetd treatment for VHL syndrome. Lenvatinib (LEN), an oral small-molecule multiple TKI, and proteinuria is one of the most common adverse events associated with LEN. We reported a case of lenvatinib-induced nephrotic syndrome in a Chinese patient with VHL syndrome. The renal biopsy was proved with thrombotic microangiopathy (TMA) and focal segmental glomerulosclerosis (FSGS)-like pattern. Drug-induced kidney injury deserves further attention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Case report: Nephrotic syndrome induced by Lenvatinib treatment in a patient with von Hippel-Lindau syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月9日

查看全文
  • Shuyu Zhang,
  • Yuehong Li,
  • Wen Wen

摘要

Von Hippel-Lindau (VHL) syndrome is an autosomal dominant hereditary disease characterized with mutiple organ tumors. Tyrosine kinase inhibitor (TKI) is one of the targetd treatment for VHL syndrome. Lenvatinib (LEN), an oral small-molecule multiple TKI, and proteinuria is one of the most common adverse events associated with LEN. We reported a case of lenvatinib-induced nephrotic syndrome in a Chinese patient with VHL syndrome. The renal biopsy was proved with thrombotic microangiopathy (TMA) and focal segmental glomerulosclerosis (FSGS)-like pattern. Drug-induced kidney injury deserves further attention.